{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:51:52Z","timestamp":1787064712103,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102270"],"award-info":[{"award-number":["82102270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.intimp.2021.108506","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T15:39:18Z","timestamp":1641569958000},"page":"108506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Blockade of Cycloxygenase-2 ameliorates sepsis induced immune-suppression by regulating myeloid-derived suppressor cells"],"prefix":"10.1016","volume":"104","author":[{"given":"Jiajun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10141","key":"10.1016\/j.intimp.2021.108506_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.immuni.2017.07.007","article-title":"Understanding Immunosuppression after Sepsis","volume":"47","author":"Fattahi","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","article-title":"Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome","volume":"45","author":"Mira","year":"2017","journal-title":"Crit Care Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.108506_b0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/SHK.0000000000001671","article-title":"Single-Cell RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets With Unique Trans-criptional Responses: A Pilot Study","volume":"55","author":"Darden","year":"2021","journal-title":"Shock."},{"issue":"3","key":"10.1016\/j.intimp.2021.108506_b0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells."},{"issue":"5","key":"10.1016\/j.intimp.2021.108506_b0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108506_b0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcibr1404664","article-title":"Parallels between cancer and infectious disease","volume":"371","author":"Phimister","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2021.108506_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2016.00037","article-title":"Myeloid-Derived Suppressor Cells in Bacterial Infections","volume":"6","author":"Ost","year":"2016","journal-title":"Front Cell Infect Microbiol."},{"issue":"6","key":"10.1016\/j.intimp.2021.108506_b0045","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/IAI.00239-12","article-title":"Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response","volume":"80","author":"Brudecki","year":"2012","journal-title":"Infect Immun."},{"key":"10.1016\/j.intimp.2021.108506_b0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.201606-1143OC","article-title":"Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in septic patients","volume":"196","author":"Uhel","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108506_b0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/SHK.0b013e31817048f7","article-title":"Cyclooxygenase 2 pathway and its therapeutic inhibition in superantigen-induced toxic shock","volume":"30","author":"Rajagopalan","year":"2008","journal-title":"Shock."},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2021.108506_b0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biopha.2016.11.102","article-title":"Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats","volume":"86","author":"Ozer","year":"2017","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.intimp.2021.108506_b0070","first-page":"37","article-title":"Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis","volume":"48","author":"Tunctan","year":"2003","journal-title":"Pharmacol Res."},{"issue":"12","key":"10.1016\/j.intimp.2021.108506_b0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/PL00012435","article-title":"Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation","volume":"51","author":"Pinheiro","year":"2002","journal-title":"Inflamm Res."},{"key":"10.1016\/j.intimp.2021.108506_b0080","article-title":"Parecoxib inhibits inflammatory responses in a mouse model of sepsis","author":"Sun","year":"2020","journal-title":"FEBS Open Bio"},{"issue":"6-7","key":"10.1016\/j.intimp.2021.108506_b0085","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/08820139.2012.695417","article-title":"PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells","volume":"41","author":"Obermajer","year":"2012","journal-title":"Immunol Invest."},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nprot.2008.214","article-title":"Immunodesign of experimental sepsis by cecal ligation and puncture","volume":"4","author":"Rittirsch","year":"2009","journal-title":"Nat Protocol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108506_b0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1258\/002367799780487887","article-title":"Interference of pain control employing opioids in in vivo immunological experiments","volume":"33","author":"Piersma","year":"1999","journal-title":"Lab Anim."},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00005373-199808000-00003","article-title":"Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection","volume":"45","author":"Shoup","year":"1998","journal-title":"J Trauma."},{"issue":"3","key":"10.1016\/j.intimp.2021.108506_b0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00024382-200014030-00023","article-title":"Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival","volume":"14","author":"Mack Strong","year":"2000","journal-title":"Shock."},{"issue":"6","key":"10.1016\/j.intimp.2021.108506_b0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/01.shk.0000235130.82363.ed","article-title":"Pneumonia after cecal ligation and puncture: a clinically relevant \u201ctwo-hit\u201d model of sepsis","volume":"26","author":"Muenzer","year":"2006","journal-title":"Shock."},{"key":"10.1016\/j.intimp.2021.108506_b0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cyto.b.21270","article-title":"Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy","volume":"90","author":"Monneret","year":"2015","journal-title":"Cytom B Clin Cytom."},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","article-title":"Myeloid-derived suppressor cell heterogeneity and subset definition","volume":"22","author":"Peranzoni","year":"2010","journal-title":"Curr Opin Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.147.1.22","article-title":"Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells","volume":"147","author":"Hestdal","year":"1991","journal-title":"J Immunol."},{"key":"10.1016\/j.intimp.2021.108506_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2021.04.025","article-title":"All-trans-retinoic acid restores CD4+ T cell response after sepsis by inhibiting the expansion and activation of myeloid-derived suppressor cells","volume":"136","author":"Liu","year":"2021","journal-title":"Mol Immunol."},{"key":"10.1016\/j.intimp.2021.108506_b0135","first-page":"101","article-title":"Delayed-type hypersensitivity models in mice","volume":"1031","author":"Allen","year":"2013","journal-title":"MethodsMol Biol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200645020-00003","article-title":"Pharmacokinetic interaction between levoflo-xacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation","volume":"45","author":"Federico","year":"2006","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"10.1016\/j.intimp.2021.108506_b0145","doi-asserted-by":"crossref","first-page":"e62265","DOI":"10.1371\/journal.pone.0062265","article-title":"Dynamics of peripheral blood lymphocyte subpopulations in the acute and subacute phase of Legionnaires' disease","volume":"8","author":"de Jager","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.intimp.2021.108506_b0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.160.1.316","article-title":"Legionella pneumophila infection in intratra- cheally inoculated T cell-depleted or -non- depleted A\/J mice","volume":"160","author":"Susa","year":"1998","journal-title":"J Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108506_b0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nri.2016.147","article-title":"Programmed cell death as a defence against infection","volume":"17","author":"Jorgensen","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.intimp.2021.108506_b0160","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol."},{"issue":"1-2","key":"10.1016\/j.intimp.2021.108506_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2006.12.004","article-title":"Prostacyclin in sepsis: a systematic review","volume":"83","author":"Zardi","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.intimp.2021.108506_b0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1471-4906(01)02154-8","article-title":"Prostaglandins as modulators of immunity","volume":"23","author":"Harris","year":"2002","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.53.082901.103952","article-title":"Cyclooxygenase-2: a therapeutic target","volume":"53","author":"Turini","year":"2002","journal-title":"Annu Rev Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.108506_b0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1164\/rccm.201708-1701LE","article-title":"Tempering the Clinical Effects of Early Myeloid-derived Suppressor Cell Expansion in Severe Sepsis and Septic Shock","volume":"197","author":"Patel","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108506_b0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/SLA.0000000000001783","article-title":"Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis\/septic shock","volume":"265","author":"Mathias","year":"2017","journal-title":"Ann Surg."},{"key":"10.1016\/j.intimp.2021.108506_b0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodriguez","year":"2008","journal-title":"Immunol. Rev."},{"issue":"6\u20137","key":"10.1016\/j.intimp.2021.108506_b0195","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol Invest"},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0200","doi-asserted-by":"crossref","first-page":"721s","DOI":"10.1158\/1078-0432.CCR-06-2197","article-title":"Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma","volume":"13","author":"Ochoa","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4049\/jimmunol.168.2.689","article-title":"Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism","volume":"168","author":"Mazzoni","year":"2002","journal-title":"J Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108506_b0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1189\/jlb.0510303","article-title":"Editorial: PGE2-producing MDSC: a role in tumor progression?","volume":"88","author":"Serafini","year":"2010","journal-title":"J Leukocyte Biol."},{"issue":"7-8","key":"10.1016\/j.intimp.2021.108506_b0215","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.intimp.2009.03.021","article-title":"Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells","volume":"9","author":"Donkor","year":"2009","journal-title":"Int Immunopharmacol."},{"issue":"20","key":"10.1016\/j.intimp.2021.108506_b0220","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","article-title":"Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells","volume":"118","author":"Obermajer","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.intimp.2021.108506_b0225","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE 2 -Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.intimp.2021.108506_b0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11596-014-1264-6","article-title":"Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress","volume":"34","author":"Li","year":"2014","journal-title":"J Huazhong Univ Sci Technolog Med Sci."},{"issue":"6","key":"10.1016\/j.intimp.2021.108506_b0235","doi-asserted-by":"crossref","first-page":"e015734","DOI":"10.1136\/bmjopen-2016-015734","article-title":"The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury- induced immunosuppression in intensive care unit (ICU) critically ill patients","volume":"7","author":"Rol","year":"2017","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.intimp.2021.108506_b0240","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2710.2009.01070.x","article-title":"Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient","volume":"35","author":"Capone","year":"2010","journal-title":"J Clin Pharm Ther."},{"issue":"4","key":"10.1016\/j.intimp.2021.108506_b0245","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/138920007780655405","article-title":"A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient","volume":"8","author":"Capone","year":"2007","journal-title":"Curr Drug Metab."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:33:46Z","timestamp":1761586426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921011425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":49,"alternative-id":["S1567576921011425"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108506","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of Cycloxygenase-2 ameliorates sepsis induced immune-suppression by regulating myeloid-derived suppressor cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108506"}}